Current status of in vivo bioanalysis of nano drug delivery systems

Wang, Tingting; Zhang, Di; Sun, Dawei; Gu, Jingkai

doi:10.1016/j.jpha.2020.05.002

Cited by 43 publications

(24 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Distinguishing the encapsulated and the released drug is often problematic and there are technical difficulties in quantifying them in the complex matrices [ 40 ]. Many methods reported in the literature for assaying the release profiles of drugs from nanoparticulate systems are based on HPLC with UV-Vis and/or mass spectrometric detection [ 41 , 42 , 43 ]. This approach may also be useful for the initial evaluation of the drug’s ability to penetrate cells.…”

Section: Resultsmentioning

confidence: 99%

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

Selective therapy and controlled drug release at an intracellular level remain key challenges for effective cancer treatment. Here, we employed folic acid (FA) as a self-navigating molecule in nanoconjugates containing quantum dots (QDs) and β-cyclodextrin (β-CD) for the delivery of antitumor unsymmetrical bisacridine compound (C-2028) to lung and prostate cancers as well as normal cells. The bisacridine derivative can form the inclusion complex with β-cyclodextrin molecule, due to the presence of a planar fragment in its structure. The stability of such a complex is pH-dependent. The drug release profile at different pH values and the mechanism of C-2028 release from QDs-β-CD-FA nanoconjugates were investigated. Next, the intracellular fate of compounds and their influence on lysosomal content in the cells were also studied. Confocal Laser Scanning Microscopy studies proved that all investigated compounds were delivered to acidic organelles, the pH of which promoted an increased release of C-2028 from its nanoconjugates. Since the pH in normal cells is higher than in cancer cells, the release of C-2028 from its nanoconjugates is decreased in these cells. Additionally, we obtained the concentration profiles of C-2028 in the selected cells treated with unbound C-2028 or nanoconjugate by the HPLC analysis.

show abstract

Section: Resultsmentioning

confidence: 99%

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Inorganic NPs include metal and metal oxides, such as gold (Au), silver (Ag), platinum (Pt), iron (Fe), iron oxide (Fe 3 O 4 ), titanium oxide (TiO 2 ), copper oxide (CuO), and oxide Zinc (ZnO) [ 147 , 148 ]. For a long time, inorganic NPs have been studied for various therapeutic applications, such as anticancer and antibacterial treatment.…”

Section: Antimicrobial Nanomedicine Drug Delivery Systemsmentioning

confidence: 99%

Recent Advances in Antimicrobial Nano-Drug Delivery Systems

et al. 2022

View full text Add to dashboard Cite

Infectious diseases are among the major health issues of the 21st century. The substantial use of antibiotics over the years has contributed to the dissemination of multidrug resistant bacteria. According to a recent report by the World Health Organization, antibacterial (ATB) drug resistance has been one of the biggest challenges, as well as the development of effective long-term ATBs. Since pathogens quickly adapt and evolve through several strategies, regular ATBs usually may result in temporary or noneffective treatments. Therefore, the demand for new therapies methods, such as nano-drug delivery systems (NDDS), has aroused huge interest due to its potentialities to improve the drug bioavailability and targeting efficiency, including liposomes, nanoemulsions, solid lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, and others. Given the relevance of this subject, this review aims to summarize the progress of recent research in antibacterial therapeutic drugs supported by nanobiotechnological tools.

show abstract

“…A number of different types of nanocarriers such as liposomes, dendrimers, polymeric nanoparticles (micelles, spheres, capsules), polymeric complex nanoparticles, cyclodextrins, nano-caseins, nanocrystals, electrospun nano-fibers, electro-sprayed nano-particles, nano-spray dried particles, covalent organic frameworks, hydrogels, inorganic nanoparticles (silica, iron, gold, titanium, carbon based nanoparticles) as well as hybrid nanoparticles (organic-inorganic based structures) have been developed. The research is focused on their in vivo absorption, permeation, and release together with toxicity, residual solvents, and biological fate during digestion, absorption, and excretion [ 59 , 60 , 82 , 83 , 89 , 90 , 91 , 92 ].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Plachá

Jampílek

2021

Pharmaceutics

View full text Add to dashboard Cite

Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.

show abstract

Current status of in vivo bioanalysis of nano drug delivery systems

Cited by 43 publications

References 123 publications

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

Recent Advances in Antimicrobial Nano-Drug Delivery Systems

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Contact Info

Product

Resources

About